BMY vs ERAS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BMY and ERAS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BMY and ERAS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. It makes money primarily by selling patented branded drugs, with a portfolio that has historically leaned on blockbuster franchises such as the blood thinner Eliquis (co-marketed with Pfizer), the cancer immunotherapy Opdivo, and the multiple myeloma drug Revlimid. The company is navigating a major patent cliff as several legacy products lose exclusivity, and it is rebuilding growth through a newer portfolio that includes drugs like Reblozyl, Opdualag, Camzyos, Sotyktu, and the schizophrenia treatment Cobenfy (acquired through Karuna). Bristol Myers grows both organically through its research pipeline and through large acquisitions (Celgene, MyoKardia, Karuna, Mirati). It is headquartered in New York and operates worldwide.

Full BMY guide

Erasca, Inc. (NASDAQ: ERAS) is a clinical-stage precision oncology company developing therapies for cancers driven by the RAS/MAPK signaling pathway, one of the most common and historically hardest-to-drug drivers in tumors like non-small cell lung cancer, pancreatic cancer, and colorectal cancer. Its prioritized pipeline centers on ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, an oral pan-KRAS inhibitor, both in Phase 1 trials (AURORAS-1 and BOREALIS-1). The company reported positive preliminary Phase 1 dose-escalation data for ERAS-0015 in 2026, showing responses in KRAS-mutant lung and pancreatic cancer, and in mid-2026 it discontinued its former lead asset naporafenib and terminated the related Novartis license to concentrate resources on the RAS-targeting franchise.

Full ERAS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BMY drivers: New product portfolio ramp; Oncology and immunology depth.
• ERAS drivers: RAS/MAPK is a large, underserved target; Early ERAS-0015 data and registration plans.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. For ERAS, erasca is pre-revenue and unprofitable, so its value depends on clinical trials that can fail at any phase, and single disappointing readouts can move the stock sharply.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BMY if you believe its drivers more; ERAS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BMY and ERAS guides.

BMY. Bristol Myers tends to trade at a low forward earnings multiple relative to large-cap pharma peers, reflecting market skepticism about its ability to replace patent-cliff revenue. The high dividend yield and strong free cash flow are the bull-case anchors, while the depressed valuation reflects the bear case that legacy declines outrun newer products.

ERAS. Because Erasca has no product sales, standard valuation multiples like P/E do not apply, and the company is valued on its cash position and the perceived probability that its RAS pipeline succeeds. The heavy Q1 2026 net loss was inflated by a large one-time licensing milestone, while underlying operating spend is more modest. The mid-2026 equity raise pushed projected runway past 2028 but increased shares outstanding.

Headline figures (approximate, early 2026): BMY shows revenue (ttm) ~$48 billion, operating margin ~20% (varies with acquisition charges), net income (ttm) volatile, pressured by large acquisition write-offs, dividend yield ~4-5%; ERAS shows product revenue ~$0 (no approved products), q1 2026 net loss ~$183M (incl. ~$150M licensing charge), q1 2026 r&d (ex one-time item) ~$27M, cash (end q1 2026) ~$408M.

BMY and ERAS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BMY and ERAS exposure against your real portfolio. It is not an investment adviser.